FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:34-43 January 5, 2006 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cannistra, S. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Standard chemotherapy for newly diagnosed ovarian cancer is a platinum–taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer.

Methods We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm to receive 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period followed by either 75 mg of intravenous cisplatin per square meter on day 2 (intravenous-therapy group) or 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 (intraperitoneal-therapy group). Treatment was given every three weeks for six cycles. Quality of life was assessed.

Results Of 429 patients who underwent randomization, 415 were eligible. Grade 3 and 4 pain, fatigue, and hematologic, gastrointestinal, metabolic, and neurologic toxic effects were more common in the intraperitoneal-therapy group than in the intravenous-therapy group (P0.001). Only 42 percent of the patients in the intraperitoneal-therapy group completed six cycles of the assigned therapy, but the median duration of progression-free survival in the intravenous-therapy and intraperitoneal-therapy groups was 18.3 and 23.8 months, respectively (P=0.05 by the log-rank test). The median duration of overall survival in the intravenous-therapy and intraperitoneal-therapy groups was 49.7 and 65.6 months, respectively (P=0.03 by the log-rank test). Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment.

Conclusions As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.

Source Information

From the Johns Hopkins Kimmel Cancer Center, Baltimore (D.K.A.); the Gynecologic Oncology Group Statistical and Data Center (B.B., H.Q.H.) and Gynecologic Oncology (S.L.), Roswell Park Cancer Institute, Buffalo, N.Y.; the University of California, Irvine, Irvine (L.W.); the New York–Presbyterian Hospital, Weill Medical College of Cornell University, New York (R.B.); Ohio State University, Columbus (L.J.C.); the University of Oklahoma, Oklahoma City (J.L.W.); and the Division of Gynecologic Oncology, University of California, Irvine, Orange (R.A.B.).

Address reprint requests to Denise Mackey at the Gynecologic Oncology Group, Administrative Office, 4 Penn Ctr., 1600 JFK Blvd., Ste. 1020, Philadelphia, PA 19103, or at dmackey{at}gog.org.

Full Text of this Article

Related Letters:

Intraperitoneal Chemotherapy for Ovarian Cancer
Ozols R. F., Bookman M. A., Young R. C., de Castro G. Jr., Snitcovsky I. M., Federico M. H.H., Armstrong D. K., Bundy B., Walker J.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1641-1643, Apr 13, 2006. Correspondence

This article has been cited by other articles:

• Ishigami, H., Kitayama, J., Kaisaki, S., Hidemura, A., Kato, M., Otani, K., Kamei, T., Soma, D., Miyato, H., Yamashita, H., Nagawa, H. (2009). Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 0: mdp260v1-mdp260 [Abstract] [Full Text]  
• ZEIMET, A. G., REIMER, D., RADL, A. C., REINTHALLER, A., SCHAUER, C., PETRU, E., CONCIN, N., BRAUN, S., MARTH, C. (2009). Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer. Anticancer Res 29: 2803-2808 [Abstract] [Full Text]  
• Helm, C. W. (2009). The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. The Oncologist 14: 683-694 [Abstract] [Full Text]  
• CAVALIERE, F., GIANNARELLI, D., VALLE, M., FEDERICI, O., LIOTTA, G., PERRI, P., DI FILIPPO, F., GAROFALO, A., IALONGO, P. (2009). Peritoneal Carcinomatosis from Ovarian Epithelial Primary: Combined Aggressive Treatment. In Vivo 23: 441-446 [Abstract] [Full Text]  
• Aebi, S., Castiglione, M., On behalf of the ESMO Guidelines Working Group, (2009). Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv21-iv23 [Full Text]  
• Teneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C., Hancock, K., Messing, M. J., Boehm, K. A., Williams, A., Asmar, L. (2009). Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer. JCO 27: 1426-1431 [Abstract] [Full Text]  
• Duiker, E. W., de Vries, E. G.E., Mahalingam, D., Meersma, G. J., Boersma-van Ek, W., Hollema, H., Lub-de Hooge, M. N., van Dam, G. M., Cool, R. H., Quax, W. J., Samali, A., van der Zee, A. G.J., de Jong, S. (2009). Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model. Clin. Cancer Res. 15: 2048-2057 [Abstract] [Full Text]  
• FIORENTINI, G., FILIPPESCHI, M., TURRISI, G., MAMBRINI, A., GIANNESSI, P. G., D'ALESSANDRO, M., ROSSI, S., DENTICO, P., GUADAGNI, S., CANTORE, M., MADRIGALI, A. (2009). Advanced Cancer of the Ovary: Intraperitoneal Chemotherapy as a New Therapeutical Option. In Vivo 23: 317-321 [Abstract] [Full Text]  
• Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., Nicodemus, C. F. (2009). Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. JCO 27: 418-425 [Abstract] [Full Text]  
• Jandial, D. D., Farshchi-Heydari, S., Larson, C. A., Elliott, G. I., Wrasidlo, W. J., Howell, S. B. (2009). Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1. Clin. Cancer Res. 15: 553-560 [Abstract] [Full Text]  
• Yamada, D. (2009). The Role of Surgery in Ovarian Cancer Management. Am Soc Clin Oncol Ed Book 2009: 302-307 [Abstract] [Full Text]  
• Walker, J. L. (2009). Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer. Am Soc Clin Oncol Ed Book 2009: 308-312 [Abstract] [Full Text]  
• Lu, Z., Tsai, M., Lu, D., Wang, J., Wientjes, M. G., Au, J. L.-S. (2008). Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer. J. Pharmacol. Exp. Ther. 327: 673-682 [Abstract] [Full Text]  
• Cao, L., Petrusca, D. N., Satpathy, M., Nakshatri, H., Petrache, I., Matei, D. (2008). Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29: 1893-1900 [Abstract] [Full Text]  
• Robinson, W. R., Coberly, C., Beyer, J., Lewis, A., Ballard, C. (2008). Office-Based Intraperitoneal Chemotherapy for Ovarian Cancer. J Oncol Pract 4: 225-228 [Full Text]  
• Havrilesky, L. J., Alvarez Secord, A., Darcy, K. M., Armstrong, D. K., Kulasingam, S. (2008). Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 26: 4144-4150 [Abstract] [Full Text]  
• Agarwal, A., Covic, L., Sevigny, L. M., Kaneider, N. C., Lazarides, K., Azabdaftari, G., Sharifi, S., Kuliopulos, A. (2008). Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Molecular Cancer Therapeutics 7: 2746-2757 [Abstract] [Full Text]  
• Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H., Wender, P. A. (2008). Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. USA 105: 12128-12133 [Abstract] [Full Text]  
• Krivak, T. C., Darcy, K. M., Tian, C., Armstrong, D., Baysal, B. E., Gallion, H., Ambrosone, C. B., DeLoia, J. A. (2008). Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer. JCO 26: 3598-3606 [Abstract] [Full Text]  
• Weberpals, J. I., Clark-Knowles, K. V., Vanderhyden, B. C. (2008). Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway. JCO 26: 3259-3267 [Abstract] [Full Text]  
• Diefenbach, C. S.M., Gnjatic, S., Sabbatini, P., Aghajanian, C., Hensley, M. L., Spriggs, D. R., Iasonos, A., Lee, H., Dupont, B., Pezzulli, S., Jungbluth, A. A., Old, L. J., Dupont, J. (2008). Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clin. Cancer Res. 14: 2740-2748 [Abstract] [Full Text]  
• Le Page, C., Ouellet, V., Quinn, M. C.J., Tonin, P. N., Provencher, D. M., Mes-Masson, A.-M. (2008). BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 17: 913-920 [Abstract] [Full Text]  
• Swart, A. M. C., Burdett, S., Ledermann, J., Mook, P., Parmar, M. K. B. (2008). Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann Oncol 19: 688-695 [Abstract] [Full Text]  
• Trimble, E. L., Thompson, S., Christian, M. C., Minasian, L. (2008). Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer. The Oncologist 13: 403-409 [Abstract] [Full Text]  
• Vergote, I., Amant, F., Leunen, K., Cadron, I., Van Gorp, T., Neven, P., Berteloot, P. (2008). Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. The Oncologist 13: 410-414 [Abstract] [Full Text]  
• Landen, C. N. Jr, Birrer, M. J., Sood, A. K. (2008). Early Events in the Pathogenesis of Epithelial Ovarian Cancer. JCO 26: 995-1005 [Abstract] [Full Text]  
• Prat, A., Parera, M., Peralta, S., Perez-Benavente, M. A., Garcia, A., Gil-Moreno, A., Martinez-Palones, J. M., Roxana, I., Baselga, J., Del Campo, J. M. (2008). Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 19: 327-331 [Abstract] [Full Text]  
• Levine, E. A., Ronnett, B. M., Mansfield, P. F., Eng, C. (2008). Overview of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms. Am Soc Clin Oncol Ed Book 2008: 153-159 [Abstract] [Full Text]  
• Viswanathan, A. N., Buttin, B. M., Kennedy, A. M. (2008). Oncodiagnosis Panel: 2006: Ovarian, Cervical, and Endometrial Cancer. RadioGraphics 28: 289-307 [Full Text]  
• Schnipper, L. E. (2007). Update in Oncology. ANN INTERN MED 147: 775-782 [Full Text]  
• Bijelic, L., Jonson, A., Sugarbaker, P. H. (2007). Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 18: 1943-1950 [Abstract] [Full Text]  
• Wagner, L. I., Wenzel, L., Shaw, E., Cella, D. (2007). Patient-Reported Outcomes in Phase II Cancer Clinical Trials: Lessons Learned and Future Directions. JCO 25: 5058-5062 [Abstract] [Full Text]  
• Minasian, L. M., O'Mara, A. M., Reeve, B. B., Denicoff, A. M., Kelaghan, J., Rowland, J. H., Trimble, E. L. (2007). Health-Related Quality of Life and Symptom Management Research Sponsored by the National Cancer Institute. JCO 25: 5128-5132 [Abstract] [Full Text]  
• Lipscomb, J., Reeve, B. B., Clauser, S. B., Abrams, J. S., Watkins Bruner, D., Burke, L. B., Denicoff, A. M., Ganz, P. A., Gondek, K., Minasian, L. M., O'Mara, A. M., Revicki, D. A., Rock, E. P., Rowland, J. H., Sgambati, M., Trimble, E. L. (2007). Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward. JCO 25: 5133-5140 [Abstract] [Full Text]  
• Chi, D. S., Ramirez, P. T., Teitcher, J. B., Mironov, S., Sarasohn, D. M., Iyer, R. B., Eisenhauer, E. L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Brown, C. L., Aghajanian, C., Gershenson, D. M., Hoskins, W. J., Hricak, H., Barakat, R. R. (2007). Prospective Study of the Correlation Between Postoperative Computed Tomography Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, and Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease 1 cm or Less. JCO 25: 4946-4951 [Abstract] [Full Text]  
• Huynh, H., Teo, C. C. M., Soo, K. C. (2007). Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics 6: 2959-2966 [Abstract] [Full Text]  
• Bazzaro, M., Santillan, A., Lin, Z., Tang, T., Lee, M. K., Bristow, R. E., Shih, I.-M., Roden, R. B.S. (2007). Myosin II Co-Chaperone General Cell UNC-45 Overexpression Is Associated with Ovarian Cancer, Rapid Proliferation, and Motility. Am. J. Pathol. 171: 1640-1649 [Abstract] [Full Text]  
• Ali, S N., Ledermann, J. A (2007). Current practice and new developments in ovarian cancer chemotherapy. The Obstetrician and Gynaecologist 9: 265-269 [Abstract] [Full Text]  
• Guse, K., Ranki, T., Ala-Opas, M., Bono, P., Sarkioja, M., Rajecki, M., Kanerva, A., Hakkarainen, T., Hemminki, A. (2007). Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Molecular Cancer Therapeutics 6: 2728-2736 [Abstract] [Full Text]  
• Mobus, V., Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., Ostermann, H., Hinke, A., Ledermann, J. A. (2007). Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT. JCO 25: 4187-4193 [Abstract] [Full Text]  
• Ozols, R. F. (2007). Ovarian Cancer: Is Dose Intensity Dead?. JCO 25: 4157-4158 [Full Text]  
• Meredith, R. F., Buchsbaum, D. J., Alvarez, R. D., LoBuglio, A. F. (2007). Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer. Clin. Cancer Res. 13: 5643s-5645s [Abstract] [Full Text]  
• Winter, W. E. III, Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., McGuire, W. P. (2007). Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 25: 3621-3627 [Abstract] [Full Text]  
• Fehrmann, R. S. N., Li, X.-y., van der Zee, A. G. J., de Jong, S., te Meerman, G. J., de Vries, E. G. E., Crijns, A. P. G. (2007). Profiling Studies in Ovarian Cancer: A Review. The Oncologist 12: 960-966 [Abstract] [Full Text]  
• Odunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., Rodabaugh, K., Lele, S., Shrikant, P., Old, L. J., Gnjatic, S. (2007). Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 12837-12842 [Abstract] [Full Text]  
• Sabbatini, P. J., Ragupathi, G., Hood, C., Aghajanian, C. A., Juretzka, M., Iasonos, A., Hensley, M. L., Spassova, M. K., Ouerfelli, O., Spriggs, D. R., Tew, W. P., Konner, J., Clausen, H., Abu Rustum, N., Dansihefsky, S. J., Livingston, P. O. (2007). Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer. Clin. Cancer Res. 13: 4170-4177 [Abstract] [Full Text]  
• Cannistra, S. A., McGuire, W. P. (2007). Progress in the Management of Gynecologic Cancer. JCO 25: 2865-2866 [Full Text]  
• Rao, G., Crispens, M., Rothenberg, M. L. (2007). Intraperitoneal Chemotherapy for Ovarian Cancer: Overview and Perspective. JCO 25: 2867-2872 [Abstract] [Full Text]  
• Burger, R. A. (2007). Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer. JCO 25: 2902-2908 [Abstract] [Full Text]  
• Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., Hobbs, H. H. (2007). Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. J. Biol. Chem. 282: 18602-18612 [Abstract] [Full Text]  
• McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., Boerwinkle, E., Hobbs, H. H., Cohen, J. C. (2007). A Common Allele on Chromosome 9 Associated with Coronary Heart Disease. Science 316: 1488-1491 [Abstract] [Full Text]  
• Spano, L. J. (2007). A terrible beauty: A physician's story of ovarian cancer. cfp 53: 983-985 [Full Text]  
• Aletti, G. D., Gallenberg, M. M., Cliby, W. A., Jatoi, A., Hartmann, L. C. (2007). Current Management Strategies for Ovarian Cancer. Mayo Clin Proc. 82: 751-770 [Abstract] [Full Text]  
• Darcy, K. M., Tian, C., Reed, E. (2007). A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res. 67: 4474-4481 [Abstract] [Full Text]  
• Silber, J. H., Rosenbaum, P. R., Polsky, D., Ross, R. N., Even-Shoshan, O., Schwartz, J. S., Armstrong, K. A., Randall, T. C. (2007). Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy?. JCO 25: 1169-1175 [Abstract] [Full Text]  
• Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., Lee, Y. (2007). Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer. Clin Med Res 5: 35-44 [Abstract] [Full Text]  
• Jamieson, D., Wilson, K., Pridgeon, S., Margetts, J. P., Edmondson, R. J., Leung, H. Y., Knox, R., Boddy, A. V. (2007). NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism. Clin. Cancer Res. 13: 1584-1590 [Abstract] [Full Text]  
• Morgan, R. J. Jr., Synold, T. W., Xi, B., Lim, D., Shibata, S., Margolin, K., Schwarz, R. E., Leong, L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Tetef, M., Lin, P., Paz, B., Koczywas, M., Wagman, L., Chu, D., Frankel, P., Stalter, S., Doroshow, J. H. (2007). Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. Clin. Cancer Res. 13: 1232-1237 [Abstract] [Full Text]  
• Otterson, G. A., Villalona-Calero, M. A., Sharma, S., Kris, M. G., Imondi, A., Gerber, M., White, D. A., Ratain, M. J., Schiller, J. H., Sandler, A., Kraut, M., Mani, S., Murren, J. R. (2007). Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs. Clin. Cancer Res. 13: 1246-1252 [Abstract] [Full Text]  
• Axtell, A. E., Lee, M. H., Bristow, R. E., Dowdy, S. C., Cliby, W. A., Raman, S., Weaver, J. P., Gabbay, M., Ngo, M., Lentz, S., Cass, I., Li, A. J., Karlan, B. Y., Holschneider, C. H. (2007). Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer. JCO 25: 384-389 [Abstract] [Full Text]  
• Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., Cella, D. (2007). Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 25: 437-443 [Abstract] [Full Text]  
• Markman, M. (2007). New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer. The Oncologist 12: 186-190 [Abstract] [Full Text]  
• Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J., Bonner, J., Curran, W. J. Jr, Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., Markman, M., Mayer, R. J., Raghavan, D., Reaman, G. H., Sawaya, R., Schilsky, R. L., Schuchter, L. M., Sweetenham, J. W., Vahdat, L. T., Winn, R. J. (2007). Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology. JCO 25: 146-162 [Abstract] [Full Text]  
• Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P. A. (2006). Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments.. JNCI J Natl Cancer Inst 98: 1655-1663 [Abstract] [Full Text]  
• Flessner, M. F., Deverkadra, R., Smitherman, J., Li, X., Credit, K. (2006). In vivo determination of diffusive transport parameters in a superfused tissue. Am. J. Physiol. Renal Physiol. 291: F1096-F1103 [Abstract] [Full Text]  
• Cohen, J. C. (2006). Genetic Approaches to Coronary Heart Disease. J Am Coll Cardiol 48: A10-A14 [Abstract] [Full Text]  
• Gore, M., du Bois, A., Vergote, I. (2006). Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. JCO 24: 4528-4530 [Full Text]  
• Armstrong, D. K., Brady, M. F. (2006). Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time. JCO 24: 4531-4533 [Full Text]  
• Leyton, J., Lockley, M., Aerts, J. L., Baird, S. K., Aboagye, E. O., Lemoine, N. R., McNeish, I. A. (2006). Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging.. Cancer Res. 66: 9178-9185 [Abstract] [Full Text]  
• Pectasides, D., Pectasides, E., Economopoulos, T. (2006). Fallopian Tube Carcinoma: A Review. The Oncologist 11: 902-912 [Abstract] [Full Text]  
• Qian, X., LaRochelle, W. J., Ara, G., Wu, F., Petersen, K. D., Thougaard, A., Sehested, M., Lichenstein, H. S., Jeffers, M. (2006). Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.. Molecular Cancer Therapeutics 5: 2086-2095 [Abstract] [Full Text]  
• Krasner, C. N., Roche, M., Horowitz, N. S., Supko, J. G., Lee, S. I., Oliva, E. (2006). Case 11-2006 -- A 54-Year-Old Woman with a Mass in the Pelvis. NEJM 354: 1615-1625 [Full Text]  
• Ozols, R. F., Bookman, M. A., Young, R. C., de Castro, G. Jr., Snitcovsky, I. M., Federico, M. H.H., Armstrong, D. K., Bundy, B., Walker, J. (2006). Intraperitoneal Chemotherapy for Ovarian Cancer. NEJM 354: 1641-1643 [Full Text]  
• (2006). Intraperitoneal Chemotherapy for Ovarian Cancer. JWatch Women's Health 2006: 2-2 [Full Text]  
• Markman, M., Walker, J. L. (2006). Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of Treatment. JCO 24: 988-994 [Full Text]  
• (2006). Intraperitoneal Chemotherapy for Ovarian Cancer Prolongs Survival. JWatch General 2006: 1-1 [Full Text]  
• Cannistra, S. A. (2006). Intraperitoneal Chemotherapy Comes of Age. NEJM 354: 77-79 [Full Text]